Andersen Global styrker sin tilstedeværelse i Den Dominikanske Republik med tilføjelse af Valumonics
Andersen Global forbedrer sine muligheder i Den Dominikanske Republik gennem en samarbejdsaftale med Valumonics, en virksomhed med speciale i værdiansættelse, fusioner og opkøb, udformning og implementering af finansiel strategi, ejendomsplanlægning og selskabsret.
Valumonics blev grundlagt i 2010 af administrerende partner Tomás Fernández W. og har kontor i Santo Domingo. Valumonics arbejder med virksomheder, finansielle institutioner, investeringsselskaber og enkeltpersoner inden for en bred vifte af brancher og servicerer kunder på både lokale og internationale markeder.
"Vores mål er at give kunderne uafhængige og tværfaglige integrerede tjenester," siger Tomás. "Vi ser frem til at skabe stærke forretningsrelationer med medlems- og samarbejdsvirksomhederne i Andersen Global og være en strategisk rådgiver for familier og førende virksomheder på det dominikanske marked."
Global Chairman og CEO for Andersen Mark L. Vorsatz tilføjer: "Den Dominikanske Republik har en af de hurtigst voksende økonomier i Latinamerika. Tomás bringer stor erfaring fra tiden, hvor han arbedede med de fire store i branchen, og nu leder han et team med et indgående kendskab til markedet. Tilføjelsen af virksomheden styrker vores kapacitet i Den Dominikanske Republik og styrker vores evne til at dække de skiftende behov hos kunder i regionen."
Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skattejurister samt skatte- og værdiansættelseseksperter i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 18.000 eksperter i hele verden og en tilstedeværelse på over 500 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20241219545255/da/
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Moutai's Global Brand Cultural Event Concludes in Italy22.12.2024 18:10:00 CET | Press release
The 2024 Global Brand Cultural Event hosted by Kweichow Moutai Group recently concluded successfully in Italy. Leveraging liquor as a cultural bridge between East and West, the event charted new pathways and milestones for Chinese brands, exemplified by Kweichow Moutai Group, in their global outreach. It also fostered deeper cultural exchange and mutual understanding between China and Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241222852417/en/ Gao Shan introduced Moutai to the guests at the event in Rome. (Photo: Business Wire) As part of the event, Moutai organized two grand themed tasting dinners in Milan and Rome. Gao Shan, Chairman of the Labor Union of Kweichow Moutai Distillery (Group) Co., Ltd., highlighted Italy's longstanding support in Moutai’s international journey, noting that the brand has been exported to Italy since the 1970s. Quoting Italian President Sergio Mattarella during his visit to China, Ga
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press release
- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and t
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press release
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum